Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: CALM3

Gene summary for CALM3

Gene summary.

Gene information	Species	Human
	Gene symbol	CALM3
	Gene ID	808
	Gene name	calmodulin 3
	Gene Alias	CALM
	Cytomap	19q13.32
	Gene Type	protein-coding
	GO ID	GO:0000086
	UniProtAcc	Q96HY3

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
808	CALM3	GSM4909281	Human	Breast	IDC	8.47e-08	3.90e-01	0.21
808	CALM3	GSM4909288	Human	Breast	IDC	6.95e-03	2.01e-01	0.0988
808	CALM3	GSM4909291	Human	Breast	IDC	8.07e-48	1.08e+00	0.1753
808	CALM3	GSM4909296	Human	Breast	IDC	3.19e-03	-4.61e-02	0.1524
808	CALM3	GSM4909298	Human	Breast	IDC	9.37e-09	3.49e-01	0.1551
808	CALM3	GSM4909301	Human	Breast	IDC	1.75e-25	6.45e-01	0.1577
808	CALM3	GSM4909304	Human	Breast	IDC	3.46e-08	3.06e-01	0.1636
808	CALM3	GSM4909306	Human	Breast	IDC	5.51e-04	3.01e-01	0.1564
808	CALM3	GSM4909307	Human	Breast	IDC	1.56e-07	3.71e-01	0.1569
808	CALM3	GSM4909308	Human	Breast	IDC	8.96e-24	6.40e-01	0.158
808	CALM3	GSM4909311	Human	Breast	IDC	5.87e-17	7.58e-02	0.1534
808	CALM3	GSM4909312	Human	Breast	IDC	6.67e-10	3.05e-01	0.1552
808	CALM3	GSM4909316	Human	Breast	IDC	2.28e-04	3.90e-01	0.21
808	CALM3	GSM4909318	Human	Breast	IDC	1.39e-02	3.86e-01	0.2031
808	CALM3	GSM4909319	Human	Breast	IDC	1.64e-17	-1.68e-01	0.1563
808	CALM3	GSM4909320	Human	Breast	IDC	3.95e-02	2.03e-01	0.1575
808	CALM3	GSM4909321	Human	Breast	IDC	4.98e-10	2.48e-01	0.1559
808	CALM3	brca2	Human	Breast	Precancer	9.20e-04	2.39e-01	-0.024
808	CALM3	M1	Human	Breast	IDC	1.41e-05	4.48e-01	0.1577
808	CALM3	NCCBC14	Human	Breast	DCIS	5.74e-08	2.32e-01	0.2021

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00325162	Cervix	CC	positive regulation of phosphoprotein phosphatase activity	8/2311	21/18723	2.44e-03	1.71e-02	8
GO:00433888	Cervix	CC	positive regulation of DNA binding	15/2311	56/18723	2.60e-03	1.80e-02	15
GO:00484883	Cervix	CC	synaptic vesicle endocytosis	16/2311	62/18723	2.87e-03	1.91e-02	16
GO:01402383	Cervix	CC	presynaptic endocytosis	16/2311	62/18723	2.87e-03	1.91e-02	16
GO:00171574	Cervix	CC	regulation of exocytosis	39/2311	202/18723	2.90e-03	1.93e-02	39
GO:00181076	Cervix	CC	peptidyl-threonine phosphorylation	25/2311	116/18723	3.59e-03	2.30e-02	25
GO:00989018	Cervix	CC	regulation of cardiac muscle cell action potential	9/2311	27/18723	3.82e-03	2.41e-02	9
GO:00973059	Cervix	CC	response to alcohol	46/2311	253/18723	4.40e-03	2.69e-02	46
GO:00182106	Cervix	CC	peptidyl-threonine modification	26/2311	125/18723	4.98e-03	2.97e-02	26
GO:00019752	Cervix	CC	response to amphetamine	10/2311	33/18723	5.07e-03	3.00e-02	10
GO:00551174	Cervix	CC	regulation of cardiac muscle contraction	18/2311	77/18723	5.15e-03	3.03e-02	18
GO:00140754	Cervix	CC	response to amine	13/2311	49/18723	5.34e-03	3.10e-02	13
GO:00902578	Cervix	CC	regulation of muscle system process	45/2311	252/18723	6.73e-03	3.70e-02	45
GO:0051279	Cervix	CC	regulation of release of sequestered calcium ion into cytosol	18/2311	79/18723	6.82e-03	3.74e-02	18
GO:00603154	Cervix	CC	negative regulation of ryanodine-sensitive calcium-release channel activity	5/2311	11/18723	6.92e-03	3.74e-02	5
GO:00347645	Cervix	CC	positive regulation of transmembrane transport	40/2311	219/18723	6.97e-03	3.76e-02	40
GO:00068873	Cervix	CC	exocytosis	59/2311	352/18723	8.74e-03	4.48e-02	59
GO:00364655	Cervix	CC	synaptic vesicle recycling	17/2311	75/18723	8.87e-03	4.53e-02	17
GO:005123524	Cervix	N_HPV	maintenance of location	33/534	327/18723	3.40e-10	2.21e-07	33
GO:005165124	Cervix	N_HPV	maintenance of location in cell	25/534	214/18723	2.49e-09	7.88e-07	25

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501218	Breast	Precancer	Parkinson disease	99/684	266/8465	3.58e-42	5.65e-40	4.33e-40	99
hsa0501016	Breast	Precancer	Alzheimer disease	103/684	384/8465	1.03e-29	4.66e-28	3.57e-28	103
hsa0502216	Breast	Precancer	Pathways of neurodegeneration - multiple diseases	112/684	476/8465	6.96e-27	2.44e-25	1.87e-25	112
hsa0516718	Breast	Precancer	Kaposi sarcoma-associated herpesvirus infection	36/684	194/8465	1.68e-06	2.53e-05	1.94e-05	36
hsa0491518	Breast	Precancer	Estrogen signaling pathway	28/684	138/8465	4.10e-06	5.39e-05	4.13e-05	28
hsa0541818	Breast	Precancer	Fluid shear stress and atherosclerosis	28/684	139/8465	4.74e-06	6.00e-05	4.59e-05	28
hsa0541718	Breast	Precancer	Lipid and atherosclerosis	37/684	215/8465	7.64e-06	9.29e-05	7.12e-05	37
hsa042189	Breast	Precancer	Cellular senescence	29/684	156/8465	1.66e-05	1.69e-04	1.30e-04	29
hsa05031	Breast	Precancer	Amphetamine addiction	14/684	69/8465	1.05e-03	7.35e-03	5.63e-03	14
hsa0516316	Breast	Precancer	Human cytomegalovirus infection	32/684	225/8465	1.13e-03	7.57e-03	5.80e-03	32
hsa0497114	Breast	Precancer	Gastric acid secretion	13/684	76/8465	7.35e-03	4.07e-02	3.12e-02	13
hsa0501219	Breast	Precancer	Parkinson disease	99/684	266/8465	3.58e-42	5.65e-40	4.33e-40	99
hsa0501017	Breast	Precancer	Alzheimer disease	103/684	384/8465	1.03e-29	4.66e-28	3.57e-28	103
hsa0502217	Breast	Precancer	Pathways of neurodegeneration - multiple diseases	112/684	476/8465	6.96e-27	2.44e-25	1.87e-25	112
hsa0516719	Breast	Precancer	Kaposi sarcoma-associated herpesvirus infection	36/684	194/8465	1.68e-06	2.53e-05	1.94e-05	36
hsa0491519	Breast	Precancer	Estrogen signaling pathway	28/684	138/8465	4.10e-06	5.39e-05	4.13e-05	28
hsa0541819	Breast	Precancer	Fluid shear stress and atherosclerosis	28/684	139/8465	4.74e-06	6.00e-05	4.59e-05	28
hsa0541719	Breast	Precancer	Lipid and atherosclerosis	37/684	215/8465	7.64e-06	9.29e-05	7.12e-05	37
hsa0421814	Breast	Precancer	Cellular senescence	29/684	156/8465	1.66e-05	1.69e-04	1.30e-04	29
hsa050311	Breast	Precancer	Amphetamine addiction	14/684	69/8465	1.05e-03	7.35e-03	5.63e-03	14

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

CALM3

SNV

Missense_Mutation

novel

c.214N>T

p.Met72Leu

p.M72L

P62158

protein_coding

tolerated_low_confidence(0.66)

benign(0.015)

TCGA-C5-A8YQ-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

CALM3

SNV

Missense_Mutation

c.27N>C

p.Gln9His

p.Q9H

P62158

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.625)

TCGA-DR-A0ZM-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unspecific

Cisplatin

CALM3

SNV

Missense_Mutation

novel

c.150N>T

p.Gln50His

p.Q50H

P62158

protein_coding

deleterious_low_confidence(0.05)

benign(0.054)

TCGA-MA-AA42-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

CALM3

SNV

Missense_Mutation

novel

c.150G>T

p.Gln50His

p.Q50H

P62158

protein_coding

deleterious_low_confidence(0.05)

benign(0.054)

TCGA-AP-A1DK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

CALM3

SNV

Missense_Mutation

novel

c.31G>A

p.Ala11Thr

p.A11T

P62158

protein_coding

deleterious_low_confidence(0.02)

benign(0.009)

TCGA-AX-A06F-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

CALM3

SNV

Missense_Mutation

novel

c.265G>A

p.Ala89Thr

p.A89T

P62158

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.774)

TCGA-AX-A1CE-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unspecific

Paclitaxel

CALM3

SNV

Missense_Mutation

novel

c.107T>C

p.Val36Ala

p.V36A

P62158

protein_coding

deleterious_low_confidence(0.03)

possibly_damaging(0.842)

TCGA-B5-A3FA-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

CALM3

SNV

Missense_Mutation

novel

c.319C>T

p.Arg107Cys

p.R107C

P62158

protein_coding

tolerated_low_confidence(0.07)

benign(0.015)

TCGA-EY-A215-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

CALM3

SNV

Missense_Mutation

novel

c.35A>G

p.Glu12Gly

p.E12G

P62158

protein_coding

deleterious_low_confidence(0.01)

probably_damaging(0.981)

TCGA-FI-A2F4-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

CALM3

SNV

Missense_Mutation

novel

c.178G>C

p.Gly60Arg

p.G60R

P62158

protein_coding

deleterious_low_confidence(0.05)

possibly_damaging(0.654)

TCGA-37-A5EL-01

Lung

lung squamous cell carcinoma

Male

<65

I/II

Chemotherapy

temodal

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1